







L Rethinking the terminology of mechanical circulatory supportNader Moazami, MD,a and David Feldman, MD, PhDbMechanical circulatory support (MCS) has continued to
grow to become one of the most important advanced ther-
apy options for patients with end-stage heart failure. Con-
tinued improvements in survival outcomes, coupled with
declining adverse events, hold the promise of advancing
this therapy further into the mainstream of our daily prac-
tice. Guidelines are expected to be published by all major
organizations, including the International Society for Heart
and Lung Transplantation, American Heart Association and
American College of Cardiology Task Force, and the Heart
Failure Society of America. It is certainly foreseeable that
the guidelines would recommend that any patient with
end-stage heart failure that is refractory to continued med-
ical treatment be evaluated by an expert team of cardiologist
and surgeons for MCS. These changes will probably in-
crease the number of referrals for this therapy. Continued
advances in the field related to development of totally im-
plantable pumps and improved battery life will make this
therapy even more socially acceptable to patients. In the
near future, MCS could potentially replace heart transplan-
tation as the therapy of choice or the new criterion standard
treatment for end-stage heart failure.
To keep up with this advancing field, our MCS terminol-
ogy should evolve to accommodate the needs of the
profession and also take into account the desires and the
psychosocial and societal needs of the community in which
we practice. The MCS lexicon is full of terms and abbrevi-
ations that are familiar to us in the field but are a foreign lan-
guage to most physicians and patients alike. Terms such as
bridge to transplant, bridge to recovery, bridge to decision,
bridge to candidacy, and finally destination therapy are
used routinely by those of us in this field. The terminology
has become so ingrained in the field that all regulatory bod-
ies, both governmental and nongovernmental agencies, are
attached to these specific terms in planning the course of tri-
als, determining reimbursement, and even approving the
use of devices. More importantly, however, our patients of-
ten struggle with this complex terminology. In particular,
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2 The Journal of Thoracic and Cardiovascular Surgerbeen destination therapy. Of the multiple definitions in
the Merriam-Webster dictionary,1 the phrases that perhaps
fit our context best define the word destination as follows,
‘‘Predetermined end, object, or use; ultimate design. The
place set for the end of a journey, or to which something
is sent; place or point aimed at.’’DEVICES AS AN ALTERNATIVE TO
TRANSPLANTATION
The concept of using mechanical pumps as permanent
cardiac replacements was among the visions of the early pi-
oneers of mechanical circulatory support. In 1965, the Na-
tional Heart, Lung and Blood Institute initiated a request for
proposal for development of a total artificial heart. The first
artificial heart was implanted in 1969 at the Texas Heart in-
stitute by Dr Denton Cooley, who used the pump developed
by Dr Michael DeBakey and designed by Dr Domingo
Liotta. This pump was implanted in a patient with postcar-
diotomy shock for a period of 3 days, until the patient re-
ceived a transplant. The concept of a total mechanical
heart pump made sense, because success with dialysis
(the artificial kidney) had been already achieved. In addi-
tion, cardiac transplantation was clinically not well estab-
lished because of the dismal results in its early days.
Although pumps were easier to design in the laboratory
and had been applied successfully in animal models, the hu-
man biologic interface proved to be a much more difficult
challenge to many in the fields of engineering and industry.
In addition, improved understanding of the immune system
and better pharmacotherapy finally brought cardiac trans-
plantation into the mainstream of medical therapy. Unfortu-
nately, the high complication rate associated with the
devices, along with the clinical success of heart transplanta-
tion, put a clinical end to the use of pumps as an alternative
to transplantation.
The late 1980s to early 1990s witnessed a resurgence of
this dream as success of using pulsatile left ventricular as-
sist devices for stabilizing patients until successful trans-
plantation became a reality. Once again, the excitement in
this area led to proliferation of centers interested in advanc-
ing this technology. The high success rate eventually cre-
ated a resurgence of interest in considering device therapy
for patients who were not suitable candidates for heart
transplantation. It appears that the term destination therapy
was coined in during development of the landmark Ran-
domized Evaluation of Mechanical Assistance for the
Treatment of Congestive Heart Failure (REMATCH) trial,
which eventually led in 2002 to the approval of the first de-
vice ever for patients with end-stage heart failure whoy c July 2012







Lfailure of medical therapy.2 Subsequently, the HeartMate II
trial was completed, and that device was approved for des-
tination therapy in January of 2010. Data from the Inter-
agency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) registry have demonstrated in-
creases both in the number of centers implanting pumps
and in the number of patients receiving pumps.3
TERMINOLOGY OF MCS
Currently, several trials are ongoing or are in various
phases of negotiationwith the Food andDrugAdministration
for the proper designation of devices and selection of patients
to be enrolled in these trials. There continues to be an insis-
tence on using the same old confusing jargon that has re-
mained in our field. Although initially these terms were
acceptable and allowed us to think about treatment options
by putting patients in different categories, in the current era
with its better pumps, this terminology is outdated and con-
fusing to patients and referring physicians in the community.
A recent patient seen in the office, whose device was im-
planted as destination therapy, was inquiring about a change
in her status. Tearfully, she said, ‘‘When you are a bridge
there is hope, destination feels like you hit the wall. Why
don’t you call it a journey, rather than a destination?’’
It is time for our professional community to rethink the
common terminology that we have gotten so used to and
redirect it so that it is simplified for all patients, physicians,
and regulatory and nonregulatory bodies involved with
medical decisions and payment. An indication of pump
placement for mechanical circulatory support of the failing
heart refractory to medical therapy should be the sole needThe Journal of Thoracic andfor considering long-term ventricular assist device place-
ment. This community recognizes that a patient’s status
will be clarified with time. In fact, most of us recognize
that those who recover should be considered for left ven-
tricular assist device explantation and that future therapy
aimed at adjunct pharmacologic and biologic interventions
(such as stem cell therapy) could potentially make that an
option for many patients regardless of our previously de-
termined artificial initial designation of these patients.
On the other hand, some patients will truly be candidates
for transplantation whereas others will live with the
pump as the designated therapy. For those who live with
the pump, exchange is always an option if complications
arise, and the first pump is not the ‘‘destination’’ implied
by the current terminology. These principles are known
and currently widely practiced among the MCS commu-
nity of cardiologists and surgeons. It is now time to
move them to the mainstream. We propose that a single
designation for MCS indication be developed and put
into practice, which would simply be end-stage heart fail-
ure refractory to medical therapy. The rest of the terms are
no longer needed.References
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